Ceesay Abraham sold $2.4M of RAPP
Ceesay Abraham (Chief Executive Officer) sold 51,499 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $47.25 ($45.97–$48.62, $2.43M total) across 5 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CEO’s open-market sale totaling $2.43M across five trades at prices ranging from $45.9736 to $48.6229, executed Aug 10 to Aug 11 under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity for sentiment, but this filing alone does not change the company’s fundamental outlook.
What to watch
The disclosure does not reveal whether the CEO’s remaining holdings are sufficient to offset future selling, nor does it provide context on compensation, tax planning, or diversification needs.
Background
The article is an SEC Form 4 insider transaction report for Rapport Therapeutics, Inc.
Ticker impact
CEO Ceesay Abraham sold $2.43M of Rapport Therapeutics shares via an open-market sale under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.
The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces signaling value versus discretionary sales. The article provides sale size and timing but no new company fundamentals.
Market effects
Minimal, as this is company-specific insider selling without new clinical, regulatory, or financing information.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially in small-cap biotech.
Key entities
- issuerRapport Therapeutics, Inc.
Subject of the Form 4 insider transaction; CEO sold shares totaling $2.43M.
- insiderCeesay Abraham
CEO and officer/director who executed the open-market sales under a 10b5-1 plan.